Effect of Extruded Cereals Enriched With β-glucan on Postprandial Plasma Glucose and Serum Insulin Responses

NCT05556837 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-07-01

No results posted yet for this study

Summary

β-glucan (BG) is a viscous dietary fiber present in barley and oats that, when added to carbohydrate containing foods, reduces the postprandial glycemic response (PPGR), which is considered to be beneficial to health. In 2011, the European Food Safety Authority (EFSA) concluded that 4g of either oat BG (OBG) or barley BG (BBG) per 30g available carbohydrate (avCHO) is required to obtain a reduction in PPGR, however this is an impractically large amount of BG to incorporate into palatable foods. A recent systematic review and meta-analysis found that doses of OBG well below 4g/30g avCHO can significantly reduce PPGR.

It is therefore hypothesized that 25g avCHO portions of cereal containing 1.4-1.5g of either OBG or BBG will elicit a statistically significantly lower PPGR compared to a control cereal containing no BG.

Conditions

  • Healthy

Interventions

OTHER

Control Cereal

A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured

OTHER

OBG Cereal

A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured

OTHER

BBG Cereal

A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured

Sponsors & Collaborators

  • INQUIS Clinical Research

    collaborator INDUSTRY
  • Cereal Partners Worldwide

    collaborator INDUSTRY
  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Thomas Wolever, DM, PhD · INQUIS Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2024-04-26
Completion
2024-06-26

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556837 on ClinicalTrials.gov